Brown-Forman Corp. Cl B (0HQ3)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 29.60 |
|---|---|
| 52-week range | 22.60 – 31.51 |
| Return, 1 month / 3 months | +11.6% / +16.0% |
| Return, 1 year / 3 years | +7.9% / −42.8% |
| Trend | Uptrend |
| RSI (14) | 73 |
| Volatility (1 year) | 37.5% |
| Worst drawdown (1 year) | -26.2% |
| Average daily value traded | 0.01M USD |
| Dividend yield | 3.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Brown-Forman makes and markets distilled spirits and wines, with a portfolio that includes Tennessee whiskey, bourbon, vodka, tequila and table wines. Its brands are sold to distributors, retailers and hospitality businesses in markets across the world. The company is based in Louisville, Kentucky, in the United States, and it manages the production, ageing and marketing of its drinks from there. Its customers include liquor stores, bars, restaurants and wholesale distributors who carry its products to consumers.
On this site Brown-Forman Corp. Cl B appears as a stock on the London Exchange (UK), code 0HQ3, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Brown-Forman Corp. Cl B (0HQ3) trades on the London Exchange in UK. It last closed at USD 29.60 on 22 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 1,789 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.9% and over the last three months it rose 16.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 12.7% | ||
| From 52-week high | -4.9% | ||
| Momentum | 62 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 16.0% | ||
| 6-month return | 5.5% | ||
| 12-month return, skipping the last month | -3.3% | ||
| Stability (higher is calmer) | 51 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 37.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.2% | ||
| Liquidity | 10 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M USD | ||
| Zero-volume days | 36.7% | ||
| Income | 69 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.1% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +2.9% |
|---|---|
| 1 month | +11.6% |
| 3 months | +16.0% |
| 6 months | +5.5% |
| 1 year | +7.9% |
| 3 years | −42.8% |
| 5 years | −52.1% |
Signals
| 50-day / 200-day average | 26.41 / 26.27 |
|---|---|
| Golden / death cross (60 days) | Golden, 3 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.75 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Sep 2026 | USD 0.2310 |
| 10 Jun 2026 | USD 0.2310 |
| 9 Mar 2026 | USD 0.2310 |
| 5 Dec 2025 | USD 0.2310 |
| 3 Sep 2025 | USD 0.2265 |
| 6 Jun 2025 | USD 0.2265 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.